|
Adult Diffuse Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The diagnosis was IDH-mutated diffuse astrocytoma, WHO grade II.
|
30079885 |
2019 |
|
Adult Diffuse Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3%; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4%; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6%; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20%; glioblastoma, IDH-mutant: 2, 100%, DA, IDH-wildtype: 9 cases, 33.3%; AA, IDH-wildtype: 20 cases, 30.0%; and glioblastoma, IDH-wildtype: 59 cases, 52.5%. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype.
|
30878754 |
2019 |
|
Adult Diffuse Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In 2 cases, there was divergent evolution of IDH1-mutated and 1p/19q-codeleted oligodendroglioma and IDH1-mutated and 1p/19q-intact diffuse astrocytoma, occurring synchronously in one case and metachronously in a second.
|
29077933 |
2018 |
|
Adult Diffuse Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma.
|
29016996 |
2018 |
|
Adult Diffuse Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Diffuse astrocytoma (DA), anaplastic astrocytoma (AA), and glioblastoma (GBM) are defined by the World Health Organization (WHO) based on IDH-mutational status.
|
28110298 |
2017 |
|
Adult Diffuse Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This retrospective study explored 56 patients undergoing tumor resection for malignant progression after previously treated IDH1-mutated WHO grade II astrocytoma.
|
28377251 |
2017 |
|
Adult Diffuse Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, both ATP2A2 overexpression and IDH1 mutation were detected in secondary glioblastoma, AA developed from DA and oligodendrogiomas with IDH1 mutation.
|
28339043 |
2017 |
|
Adult Diffuse Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The majority of glioblastomas develop rapidly with a short clinical history (primary glioblastoma IDH wild-type), whereas secondary glioblastomas progress from diffuse astrocytoma or anaplastic astrocytoma.
|
26443480 |
2016 |
|
Adult Diffuse Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A better prognosis was significantly associated with combined IDH1 mutation and MGMT methylation status (both positive vs both negative, HR 0.079 [95% CI 0.008-0.579], p=0.012), as well as histology (OG vs DA and OA, HR 0.158 [95% CI 0.022-0.674], p=0.011) and tumor size (<6 cm vs ≥6 cm, HR 0.120 [95% CI 0.017-0.595], p=0.008).
|
26276726 |
2015 |
|
Adult Diffuse Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy.
|
26243269 |
2015 |
|
Adult Diffuse Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Somatic mutations in the isocitrate dehydrogenase 1 or 2 (IDH1/IDH2) genes were detected in 96% of LGO and 91% of LGA.
|
26303387 |
2015 |
|
Adult Diffuse Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To validate mutation frequency, IDH1 gene at codon 132 was sequenced in 74 diffusely infiltrating astrocytomas: diffuse astrocytoma (DA; World Health Organization [WHO] grade II), anaplastic astrocytoma (AA; WHO grade III), and GBM (WHO grade IV).
|
22904127 |
2012 |
|
Adult Diffuse Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This retrospective study included patients with a diagnosis of WHO grade II astrocytoma and cortical infiltration and in whom initial symptoms were documented and biopsy tissue was available for IDH1/2 analysis.
|
22217666 |
2012 |